{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59","upperLimit":"82","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Adverse events/toxicities were collected during regular clinical visits. Confidence intervals for the estimate of the true number of patients suffereing from grade 3 or 4 toxicities per common terminology criteria were calculated using the Wilson interval. Ninety-five percent confidence intervals for the proportions of patients with complications (grade 3 or higher toxicities) were constructed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"OG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Toxicity and Tolerability of the Bevacizumab and Lenalidomide Combination","type":"SECONDARY","unitOfMeasure":"percentage of participants"}